Free Newsletter
Register for our Free Newsletters
Analysis, Inspection and Laboratory
Assisted/Independent Living
Clinical and Nursing Equipment
Design and Manufacture of Medical Equipment
Diagnostics Equipment, Monitoring and Test
Education, Training and Professional Services
Health Education and Patient Management
Health Estates Management
Healthcare Support and Information Services
Hygiene and Infection Control
IT and Communications in Healthcare
Medical Device Technology
Research and Development
Safety and Security
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone

Sysmex and bioMerieux create joint venture to support the Japanese in-vitro diagnostics market

BioMerieux : 10 January, 2008  (New Product)
Sysmex and bioMerieux have signed an agreement by which Sysmex will take a 34 percent equity stake in bioMerieux Japan.
The new company, called Sysmex bioMerieux will promote and commercialise the entire bioMerieux product range in Japan starting April 1, 2008. The joint venture will manage the regulatory filing and marketing activities of bioMerieux product ranges in Japan. The sales and customer service activities will be contracted out from the joint venture to Sysmex.

bioMerieux has been operating in the Japanese clinical diagnostics and industrial testing market thus far through bioMerieux Japan, a fully-owned subsidiary.

Market volume of microbiology testing in Japan is estimated at approximately 30 billion Japanese yen per year and regarded as a strategically important market, the second largest in size worldwide.

Sysmex and bioMerieux have been developing their global partnership since July 2007 when bioMerieux became a global partner to distribute Sysmex’s standardised and automated UF-1000i, urine sediment analyser to their extensive clinical microbiology customer base. The new venture reinforces the long-standing partnership between the two companies.

“We are extremely pleased to engage in this joint venture with Sysmex for the Japanese market,” declared Stephane Bancel, chief executive officer of bioMerieux. “To date, bioMerieux Japan is number 19 in the Japanese IVD market, while bioMerieux is number seven worldwide. We have been lacking scale in several critical functions like commercial operations and customer service. By partnering with the number one diagnostics company in the Japanese market, we will bring bioMerieux’s innovative products to a broader Japanese customer base. We could not have found a better partner for this key market.”

'The collaboration with bioMerieux in the Japanese market will allow us to leverage our well-reputed sales and service network and infrastructure to provide expert solutions to customers,' stated Hisashi Ietsugu, president of Sysmex. 'This agreement again confirms that the partnership between two leading companies in in-vitro diagnostics is a strategic match as both complement each other.'

Bookmark and Share
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   © 2012
Netgains Logo